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Metabolomics is the comprehensive profiling of the small molecule composition of a biological
sample. Since metabolites are often the indirect products of gene expression, this approach is being
used to provide new insights into a variety of biological systems (clinical, bioenergy, etc.). A grand
challenge for metabolomics is the complexity of the data, which often include many experimental
artifacts. This is compounded by the tremendous chemical diversity of metabolites. Identification
of each uncharacterized metabolite is in many ways its own puzzle (compared with proteomics,
which is based on predictable fragmentation patterns of polypeptides). Therefore, effective data
reduction/prioritization strategies are critical for this rapidly developing field. Here we review
liquid chromatography electrospray ionization mass spectrometry (LC/MS)-based metabolomics,
methods for feature finding/prioritization, approaches for identifying unknown metabolites, and
construction of method specific ‘Metabolite Atlases’. (J Am Soc Mass Spectrom 2010, 21,
1471–1476) © 2010 Published by Elsevier Inc. on behalf of American Society for Mass SpectrometryNature utilizes a tremendous diversity of metabo-lites, and it is estimated that there are 200,000plant metabolites alone [1]. Metabolomics is a
rapidly growing field for studying the small molecule
composition of a biological system. Liquid chromatogra-
phy coupled to electrospray ionization mass spectrometry
(LC/MS) is becoming a method of choice for profiling
metabolites in complex biological samples. This is due to
its ability to effectively ionize a breath of metabolites with
minimal fragmentation (versus gas chromatography-mass
spectroscopy (GC/MS), robustness, and ability to scale-up
to support tandem mass spectrometry based structural
studies (versus capillary electrophoresis-mass spectrome-
try (CE-MS)) [2]. However, known metabolites are typi-
cally a small portion of the data obtained in a LC/MS
metabolomics experiment (10%) [3] where the bulk are
MS-artifacts and uncharacterized metabolites.
Identification of unknown metabolites is cost and
effort intensive, often requiring preparative scale isola-
tion for nuclear magnetic resonance (NMR) studies or
extensive chemical synthesis to enable structural com-
parisons using tandem mass spectrometry (MS/MS) [4].
Therefore, it is not surprising that the majority of
reports focus on changes in metabolites that have
authentic standards or at a minimum are found in
metabolite databases. Yet, there are only a few thou-
sand commercially available analytical standards due to
lack of demand and the inherent instability of many
metabolites. These standards and the endogenous me-
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tion of endogenous metabolites. Therefore, effective
methods for prioritizing, studying, and ultimately iden-
tifying uncharacterized metabolites is a critical devel-
opment for LC/MS based metabolomics [5–10]. Here
we discuss current LC/MS metabolomic approaches
(detailed elsewhere [2, 4, 11, 12]) and their integration
into ‘Metabolite Atlases’ to facilitate annotation and
prioritization of uncharacterized metabolites.
LC/MS Based Metabolomics
The conventional metabolomics workflow is summa-
rized in Figure 1. At the heart of any mass spectrometry
experiment is the generation of gas-phase ions. Metabo-
lomics experiments primarily utilize electrospray ion-
ization (ESI) or electron ionization (EI). Each has its
advantage, EI effectively ionizes and fragments most
volatile molecules, and these fragments are easily com-
pared with large spectral databases to aid identification.
However, ESI is often preferred for profiling ‘unknown’
metabolites since this ‘soft’ desorption/ionization ap-
proach efficiently forms ‘intact’ molecular ions that aids
initial identification of unknowns. This coupled with
the high mass accuracy of many instruments (5 ppm)
facilitates the initial (‘putative’) identification of metab-
olites by searching metabolite databases [13]. This ap-
proach has been implemented in a wide range of
applications primarily related to functional genomics
and clinical studies [4, 14].
The number of metabolites detected can be increased
by chromatographic methods (i.e., reverse and normal
phase chromatography). EI is typically coupled to gas
chromatography (GC/MS), and ESI is often coupled to
Published online April 12, 2010
ass Spectrometry. Received November 13, 2009
Revised March 22, 2010
Accepted April 8, 2010
wn
1472 BOWEN AND NORTHEN J Am Soc Mass Spectrom 2010, 21, 1471–1476liquid chromatography (LC/MS) or capillary electro-
phoresis (CE-MS) to resolve complex mixtures. Though
it should be noted that Fourier transform ion cyclotron
resonance mass spectrometry (FTICR/MS) can often
resolve complex mixtures of metabolites without chro-
matography [15]. The wide range of chromatography
(LC) options allow physical separation of most mole-
cules to reduce signal suppression [16]. While reverse-
phase methods tend to utilize C18 columns, a wide
range of normal phase materials are utilized [16, 17]
e.g., popular new materials, including hydrophilic in-
teraction chromatography (HILIC) and aqueous normal
phase (ANP) have recently been developed for im-
proved separation of polar metabolites [18].
The combination of exact mass measurements and
LC retention time are used to define chromatographic/
ion features (m/z, RT) that are taken as a first approxi-
mation of a molecular identifier. Higher specificity
features are obtained through the addition of fragmen-
tation data (m/z parent, RT, m/z daughters). However, in
practice, it is difficult to obtain useful fragmentation
data for all features in an untargeted profiling experi-
ment and it is therefore useful to utilize preferred or
target lists for features of interest.
There are a variety of algorithms for defining these
‘features’ and comparing them with metabolite data-
Figure 1. Overview a typical LC/MS metabo
steps (quenching, cell lysis, extraction, etc.), LC/
concludes with structural confirmation of unknobases as discussed in more detail below. A limitation ofdefining unidentified ions as features is that both di-
mensions (m/z, RT) are method-dependent. Changes in
the LC method, mobile phase, biological matrix, etc. can
result in a new RT for the same ion or new ions
(adducts). Changes to the ionization source (i.e., frag-
mentor and capillary voltages) will change the types/
abundances of ions (adducts and neutral losses). Fur-
ther, experimental variables such as the extraction
method can have dramatic effects, requiring careful
experimentation to obtain comprehensive and repro-
ducible results [19, 20].
Since features depend on the experimental details, it
is valuable to standardize metabolomics methods and
metabolomics data reporting. This can be accomplished
by following the reporting standards defined by the
metabolomics community [21–23]. For example, exper-
imental details should be linked to the metabolite
features, which can also be linked to metabolite data-
bases, i.e., METLIN [5], KEGG [6], MetaCyc [7], the
Golm Metabolome Database [8], HMDB [9], LIPID-
MAPS [10], and MassBank (URL: http://www.massbank.
jp/) to facilitate identification. In many ways, these
efforts follow in the footsteps of other systems ap-
proaches (genomics, transcriptomics, and proteomics)
that have established mechanisms for data-sharing and
c workflow. This includes sample preparation
rofiling, feature finding, statistical analysis, and
metabolites.lomi
MS panalysis [24].
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Due to the cost and effort required to identify unknown
metabolites, only the ‘most important’ features are
selected for identification. Generally, efforts entail four
steps: first, the unique features for each sample are
computationally defined to allow comparison of abun-
dance across samples in an experiment. Second, statis-
tical methods are used to identify the largest and most
significantly changing features. Third, identified fea-
tures are annotated to assign isotopes, adducts, degra-
dation products, etc. Finally, the resulting neutral
masses are searched against metabolite databases to
identify candidates for further analysis.
In the first step, data files must be processed by
algorithms capable of identifying features that result
from the various signatures of an ionized metabolite.
Again, a feature is simply a collection of data points or
a region in m/z and time. In principle, the feature will
have a chromatogram that is Gaussian in shape, a
well defined peak, and the distribution of data points
in the feature will be narrowly distributed at a given
m/z. In practice, the characteristic shape of a metab-
olite feature can be highly varied. Features are de-
fined using a wide array of existing algorithms, such
as XCMS [25], msInspect [26], mzMine [27], commer-
cial options, and many more [28, 29]. As an open-source
application, XCMS is the most widely used of these
algorithms, and the recently described CentWave peak
finding strategy is an important development [30].
To prioritize features for subsequent identification,
statistical methods based on data clustering, dimen-
sional reduction, and multiple hypothesis testing are
used. In addition to parametric and nonparametric
hypothesis tests, these include principal component
analysis (PCA) [31], partial-least-squares discriminant
analysis (PLS-DA) [3], and self organizing networks
(GEDI) [32]. These tools can reduce the complexity of data
by allowing researchers to focus efforts on groups of features
that exhibit similar abundance patterns. One commonly
used, freely available statistical package that enables a wide
variety of data analyses is MultiExperiment Viewer (MeV)
[33]. This application is widely used for the analysis of
microarray data and has several features making it an
excellent choice for metabolomics data analysis.
Once compound specific features are defined and
annotated, the accurate neutral masses of these com-
pounds can be searched in a variety of metabolite
databases to create a list of putative identifications. The
reader is referred to a recent review for additional
discussion on metabolite databases [34]. However, there
are limitations to this approach. The databases are not
comprehensive and many contain a wide variety of
unnatural metabolites [35].
Recent works illustrate the predominant work-
flows for untargeted metabolomic profiling experi-
ments: Wikoff et al. used LC/MS and XCMS to analyze
the cerebrospinal fluid of SIV-infected macaques [36].
Unequal-variance t-tests and fold-change between theinfected and uninfected samples was used to reduce
3000 features to the 12 most important. These were
then identified using authentic standards and tandem
mass spectrometry. In another study, Tyburski et al.
used LC/MS metabolomics to study the response of
mice to -radiation exposure [37]. MarkerLynx was
used for feature identification. Self-Organizing Maps,
PCA, and PLS techniques were used to prioritize the
features affected which were subsequently identified by
comparing their fragmentation patterns with authentic
standards. These examples and others have been uti-
lized within the framework of untargeted metabolomics
[38]. In each case, definitive identification of a few
uncharacterized metabolites represents a major re-
search effort.
Current Approaches for Identifying
Unknown Metabolites
The development of MS/MS spectral databases such as
METLIN and MassBank are of great assistance in the
identification of unknown metabolites. One concern of
this approach is the consistency of fragmentation pat-
terns between instruments. Hence, it is a good practice
to obtain the authentic standard for final identification.
Unfortunately, many metabolites are neither in spectral
databases nor commercially available, making identifi-
cation of these an arduous process. The higher sensitiv-
ity of LC/MS versus NMR typically requires either
isolation/enrichment for direct structural analysis us-
ing NMR, or further mass spectrometry based struc-
tural analysis [39]. If sufficient sample is available,
enrichment may be the most direct route. However, in
many cases it is not possible to separate sufficient
quantities due to sample availability and/or complex-
ity. In these cases, it is necessary to synthesize libraries
of related hypothetical molecules and compare features
(e.g., m/z, fragmentation masses, and method specific
retention time) with the unknown metabolite [37, 40].
There are a number of approaches to obtain less
definitive structural identification. Detection of diag-
nostic fragmentation patterns is often a preferred
method [41]. Hence, the further development of
LC/MS and MS/MS databases and search algorithms
are an important goal for simplifying this process as
are computational tools for predicting structure based
on MS/MS data [42]. Stable isotopic label incorporation
or chemical derivatization can also aid in structural
confirmation based on mass shifts in specific fragments,
though this approach is not viable for many experimen-
tal situations (i.e., clinical samples) [2, 43]. For example,
if it is postulated that a metabolite contains a nitro-
gen, comparison of the metabolite from 14N versus
15N cultures can confirm the number of nitrogen atoms
per molecule and link them to specific MS/MS frag-
ments. It can also be useful to globally compare isoto-
pically labeled and unlabeled metabolite pools [44–46].
Mass shifts between labeled and unlabeled metabolites
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be used to derive empirical formulas. This can also help
differentiate metabolites from background ions (e.g., no
chemical shift suggests a background ion).
Construction of Method-Specific
Metabolite Atlases
Construction of Metabolite Atlases is simply a matter of
accumulating data from multiple experiments per-
formed on similar biological matrices (samples) using
identical LC/MS methods (Figure 2). This allows re-
searchers to leverage the same annotations across mul-
tiple experiments. For example ‘artifact’ features (i.e.,
adducts and degradation products) can be identified
once, and in the long-term, this avoids wasted effort
re-identifying nonbiological features. This approach has
the risk that some features are in fact different compounds
in the various experiments. Therefore, it is a good practice
to confirm instrument calibration, retention time stability,
and perform tandem mass spectrometry to confirm that
compounds are identical before drawing any conclusions.
Adducts can be annotated by linking features with
common mass transformations (Figure 3) [47]. Specifi-
cally, retention time, MS/MS, and mass-difference in-
Figure 2. Metabolite Atlases. Combining singl
LC/MS method-specific Metabolite Atlases requ
comparisons.
Figure 3. Experimental and higher order analy
annotations (identified compounds, adducts, is
multiple experiments and can reveal common ba
characterization.formation can be utilized to provide a signature for a
particular metabolite that is detected as multiple fea-
tures due to isotopes and experimental artifacts (ad-
ducts, neutral loss, etc.). There are computational tools
that can assist in this process to help determine the
neutral mass of the compound [48–50]. This informa-
tion is then used to annotate possible chemical formulas
(including those identified using stable isotope labels)
and information from metabolite databases (i.e., KEGG
identifiers and names). Annotations should also include
experimental details to allow subsequent comparisons
across experiments (Figure 2).
The Atlas also associates features that exhibit similar
patterns of abundance as shown in Figure 3. Correlation-
based relationships retrieve metabolite features that are
significantly different between specified samples. These
can also be correlated with protein-abundance, sample
types, or some other meta-data in the specified samples.
While a feature may not be important in the context of
a single experiment, it may be found to be important
across multiple experiments. In some cases it may be
observed that unknown features are correlated with
known metabolites, which can suggest biological asso-
ciations. This point is illustrated in a recent study by
Wren [51], where the Gene Expression Omnibus (GEO)
eriments using similar biological samples into
little effort and enables additional experimental
f Metabolite Atlases. This format allows feature
es, neutral losses, etc.) to be leveraged across
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functional associations for uncharacterized transcripts.
These types of complex queries illustrate the power and
utility of data integration across experiments.
Summary
The extent to which researchers can select the most
critical features governs the risk in making the signifi-
cant effort required to identify them. It is therefore not
surprising that the metabolomics community has in-
vested major efforts in developing approaches for the
identification of uncharacterized metabolites from sin-
gle experiments. Moving beyond these to more global
analysis requires implementation of data standards,
reporting standards, new computational tools, and the
further development of metabolite databases. Research
groups carrying out large-scale metabolomics experi-
ments can place their findings into a broader context by
constructing method-specific Metabolite Atlases. These
can then be used for annotation purposes to simplify
feature annotation and enable multi-experiment analysis.
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